Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment.

Saved in:
Bibliographic Details
Title: Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment.
Authors: Podder V; Mount Sinai Medical Center, Division of Gynecologic Oncology, Miami Beach, FL, USA., Grisham RN; Memorial Sloan Kettering Cancer Center, Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA., Coleman RL; Texas Oncology, Gynecologic Oncology, The Woodlands, TX, USA., Cobb LP; University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, USA., Monk BJ; Florida Cancer Specialists and Research Institute, Division of Gynecologic Oncology, West Palm Beach, FL, USA., Herzog TJ; University of Cincinnati Cancer Center, Division of Gynecologic Oncology, Cincinnati, OH, USA., Gershenson DM; University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, USA., Slomovitz BM; Mount Sinai Medical Center, Division of Gynecologic Oncology, Miami Beach, FL, USA. Electronic address: brian.slomovitz@msmc.com.
Source: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2025 Dec; Vol. 35 (12), pp. 101938. Date of Electronic Publication: 2025 May 15.
Publication Type: Journal Article; Review
Journal Info: Publisher: BMJ Country of Publication: United States NLM ID: 9111626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1525-1438
DOI:10.1016/j.ijgc.2025.101938